Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Cellular Immunotherapy Industry By 2029?

The market size of cellular immunotherapy has seen rapid expansion in the recent past. It is projected to escalate from a value of $5.72 billion in 2024 to $6.56 billion in 2025, with a Compound Annual Growth Rate (CAGR) standing at 14.7%. Factors such as advancement in cancer therapies, cases of successful clinical outcomes, regulatory accreditations, and an increasing occurrence of targeted diseases have contributed significantly to the growth experienced during the historical period.

The market size for cellular immunotherapy is projected to expand swiftly in the forthcoming years, reaching an estimated value of “$11.03 billion by 2029, with a compound annual growth rate (CAGR) of 13.9%. The predicted growth during this forecasted period can be credited to several factors, such as the increased focus on solid tumours, advancements in manufacturing processes, improved healthcare facilities, and increased funds allocated for research. Key trends for the forecast period include investment in research and development, data from clinical trials, and the rise of combination therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What Core Drivers Are Expected To Influence The Cellular Immunotherapy Market?

The anticipated expansion of the cellular immunotherapy market is predicted due to the increased research and successful clinical trials in this field. There is a concentrated effort amongst companies to develop novel cellular immunotherapies for a variety of diseases. As an example, the Cancer Research Institute, a non-profit organization based in the United States dedicated to the advancement of immunotherapy for the prevention, treatment, and eradication of all forms of cancer, released a report in June 2022 stating that as of April that same year, the global immuno-oncology pipeline included 2,756 active cell therapy drugs. This reflects an increase of 36% from the landscape analysis conducted in 2021, which revealed the existence of 2,031 drugs, but also demonstrates a decrease in growth from the previous year’s 43%. The remarkable growth in cellular immunotherapy development both at the clinical and preclinical stages in 2020 compared to 2019 is likely to extend the reach of cellular immunotherapy further, consequently driving the generation of higher revenues for the advancement of the market.

What Is The Segment Breakdown Of The Cellular Immunotherapy Market?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

How Are Global Trends Impacting The Development Of The Cellular Immunotherapy Market?

Firms in the cellular immunotherapy market are turning their attention towards creating off-the-shelf allogeneic therapies as a novel and more effective approach to combat cancer. These therapies, unlike autologous treatments, are derived from donor cells rather than the patient’s own cells. Benefits of these non-personalized treatments include cost efficiency, mass production, rapid development, and quality assurance. For example, in May 2022, the Switzerland-based pharmaceutical firm Novartis AG, known for its commitment to discovering, developing, manufacturing, and marketing drugs, received rapid approval from the US Food and Drug Administration (FDA) to use Kymriah (tisagenlecleucel) for treating adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more courses of systemic therapy. Additionally, Acepodia, an American cell immuno-technology company specialized in next-generation treatment, is set to initiate a phase 1 clinical trial in August 2020 for ACE1702, an allogeneic, off-the-shelf NK cell therapy intended for treating solid tumors.

Which Firms Are Driving Innovation Within The Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model